OncoMatch/Clinical Trials/NCT05319639
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Is NCT05319639 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for gastric cancer stage iv.
Treatment: Oxaliplatin · Levo-Leucovorin · 5-fluorouracil · Paclitaxel · Irinotecan · Tislelizumab — The purpose of the phase I/II study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); leucopenia count of ≥4.0×10^9/L; platelet count of ≥100×10^9/L
Kidney function
creatinine (Cr) of ≤ 1.5 UNL; creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault)
Liver function
total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis
Cardiac function
normal electrocardiogram results and no history of congestive heart failure
With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g/L (without blood transfusion during 14 days); a leucopenia count of ≥4.0×109/L; a platelet count of ≥100×109/L; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis. With normal electrocardiogram results and no history of congestive heart failure.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05319639 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages